𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial

✍ Scribed by David R. Spigel; John D. Hainsworth; Emily R. Burkett; Howard A. Burris; Denise A. Yardley; Melodie Thomas; Suzanne F. Jones; Natalie R. Dickson; Daniel C. Scullin; James E. Bradof; James R. Rubinsak; Joseph E. Brierre; F. Anthony Greco

Book ID
115076599
Publisher
CIG Media Group, LP.
Year
2005
Tongue
English
Weight
519 KB
Volume
7
Category
Article
ISSN
1525-7304

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly docetaxel in the treatment of eld
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial
✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Lisa H. Morrissey; Jo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 3 views

## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme

Weekly docetaxel versus docetaxel/gemcit
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer : A randomized phase 3 trial of the Minnie Pearl Cancer Research Network
✍ John D. Hainsworth; David R. Spigel; Cindy Farley; Dianna L. Shipley; James D. B 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract ## BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Previously untreated pat